Differences in Drug Response to Pegylated Recombinant Human Growth Hormone in Children with Growth Hormone Deficiency

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055588

Enrollment

Unknown

Registered

2022-01-14

Start date

2018-01-01

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GHD of children

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: As the group leader, our institution is undertaking the phase iv clinical trial of pegylated recombinant human growth hormone injection in the treatment of childhood growth hormone deficiency (Protocol No. Gensci201404502), All patients who participated in the program were enrolled in this study.

Exclusion criteria

Exclusion criteria: Patients who did not record medication diary card in time and did not follow the study protocol.

Design outcomes

Primary

Measure	Time frame
Metabolites were obtained by GC-TOFMS technique;	—

Countries

China

Contacts

Public ContactNi Shaoqing

Children’s Hospital, Zhejiang University School of Medicine

chnsq@zju.edu.cn+86 13868172303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026